• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Newbury Pharmaceuticals

1.92 SEK

+1.59 %

Less than 1K followers

NEWBRY

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.59 %
+36.17 %
+102.11 %
+66.96 %
+60.67 %
-30.18 %
-52.94 %
-
-84.76 %

Newbury Pharmaceuticals is a pharmaceutical company. The company develops a pipeline of in-house developed and licensed products with a focus on specialty drugs in areas such as oncology, rare diseases, and neurology. The company conducts its business within the Scandinavian market. Newbury Pharmaceuticals was founded in 2020 and has its headquarters in Lund.

Read more
Market cap
58.36M SEK
Turnover
60.64K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
8.7.
2026

Interim report Q3'26

28.10.
2026

Annual report '26

20.1.
2027

General meeting '27

Press release4/17/2026, 8:00 AM

Newbury Pharmaceuticals Secures Generic Approval for Palbociclib Newbury

Newbury Pharmaceuticals
Regulatory press release4/15/2026, 8:30 AM

Extraordinary General Meeting of Newbury Pharmaceuticals AB

Newbury Pharmaceuticals
Regulatory press release4/15/2026, 6:00 AM

Newbury Pharmaceuticals interim report September 2025 – February 2026

Newbury Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release3/26/2026, 6:30 PM

Kallelse till extra bolagsstämma i Newbury Pharmaceuticals AB

Newbury Pharmaceuticals
Regulatory press release3/26/2026, 1:00 PM

Newbury Pharmaceuticals extends and increases loan agreement to SEK 30m, convenes EGM

Newbury Pharmaceuticals
Press release3/18/2026, 3:45 PM

Newbury Pharmaceuticals has entered into a new partnership for Prucalopride tablets

Newbury Pharmaceuticals
Press release1/29/2026, 11:00 AM

Newbury Pharmaceuticals Secures 12-Month Pazopanib Tender in Denmark

Newbury Pharmaceuticals
Regulatory press release1/21/2026, 7:00 AM

Newbury Pharmaceuticals interim report September 2025 – November 2025

Newbury Pharmaceuticals
Regulatory press release1/14/2026, 10:15 AM

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB

Newbury Pharmaceuticals
Regulatory press release12/10/2025, 7:30 PM

Newbury Pharmaceuticals publishes its annual report for 2024/2025

Newbury Pharmaceuticals
Regulatory press release12/9/2025, 3:15 PM

Kallelse till årsstämma i Newbury Pharmaceuticals AB

Newbury Pharmaceuticals
Press release11/18/2025, 12:50 PM

Nordic Market Update

Newbury Pharmaceuticals
Regulatory press release11/11/2025, 12:15 PM

Newbury Pharmaceuticals appoints its founder Karl Karlsson as new CEO

Newbury Pharmaceuticals
Regulatory press release10/29/2025, 7:00 AM

Newbury Pharmaceuticals year-end report September 2024 – August 2025

Newbury Pharmaceuticals
Press release10/24/2025, 6:30 AM

Newbury Pharmaceuticals Secures Generic Approval for Mirtazapin Newbury

Newbury Pharmaceuticals
Press release10/23/2025, 12:30 PM

Newbury Pharmaceuticals Secures Generic Approval for Ivermectin Newbury

Newbury Pharmaceuticals
Press release9/23/2025, 6:30 AM

Newbury Pharmaceutical, CEO, Lars Minor, will present the company at Økonomisk Ugebrev's Life Science Conference on 24 September 2025 in Copenhagen.

Newbury Pharmaceuticals
Press release8/11/2025, 8:00 AM

Newbury Pharmaceuticals Secures Generic Approval for Melatonin Newbury

Newbury Pharmaceuticals
Regulatory press release7/9/2025, 6:00 AM

Newbury Pharmaceuticals interim report September 2024 – May 2025

Newbury Pharmaceuticals
Regulatory press release4/28/2025, 7:21 AM

Newbury Pharmaceuticals carries out a directed share issue of approximately SEK 16 million and extends the existing SEK 15 million loan agreement

Newbury Pharmaceuticals